Molecular targets of ivermectin as a potential repurposed drug in cancer therapy: A scoping review

doi:10.13105/wjma.v14.i2.121391

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

(4)

(0)

(4)

(105)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Meta-Analysis

ISSN

2308-3840

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Meta-Anal. Jun 18, 2026; 14(2): 121391
Published online Jun 18, 2026. doi: 10.13105/wjma.v14.i2.121391

Open in New Tab Full Size Figure Download Figure

Figure 1 PRISMA-scoping reviews flow diagram.

Citation: Olunga R, Jaoko W, Kipkoech R, Natalia G, Tai RJ, Mutanu L, Jengo M, Mwangi FW, Ayuma O, Anosike UG. Molecular targets of ivermectin as a potential repurposed drug in cancer therapy: A scoping review. World J Meta-Anal 2026; 14(2): 121391
URL: https://www.wjgnet.com/2308-3840/full/v14/i2/121391.htm
DOI: https://dx.doi.org/10.13105/wjma.v14.i2.121391

Olunga R, Jaoko W, Kipkoech R, Natalia G, Tai RJ, Mutanu L, Jengo M, Mwangi FW, Ayuma O, Anosike UG. Molecular targets of ivermectin as a potential repurposed drug in cancer therapy: A scoping review. World J Meta-Anal 2026; 14(2): 121391 [DOI: 10.13105/wjma.v14.i2.121391]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.